A Review of Quantitative Systems Pharmacology Models of the Coagulation Cascade: Opportunities for Improved Usability

被引:5
|
作者
Chung, Douglas [1 ]
Bakshi, Suruchi [1 ,2 ]
van der Graaf, Piet H. [1 ,2 ]
机构
[1] Certara UK Ltd, Quantitat Syst Pharmacol, Sheffield S1 2BJ, England
[2] Leiden Univ, Div Syst Pharmacol & Pharm, LACDR, NL-2300 RA Leiden, Netherlands
关键词
quantitative systems pharmacology; coagulation cascade; model reusability; mechanistic hypotheses exploration; RECOMBINANT FACTOR VIIA; TISSUE FACTOR PATHWAY; BLOOD-COAGULATION; MATHEMATICAL-MODEL; THROMBIN GENERATION; KINETIC-MODEL; EXTRINSIC PATHWAY; FACTOR-XII; ACTIVATION; SIMULATION;
D O I
10.3390/pharmaceutics15030918
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Despite the numerous therapeutic options to treat bleeding or thrombosis, a comprehensive quantitative mechanistic understanding of the effects of these and potential novel therapies is lacking. Recently, the quality of quantitative systems pharmacology (QSP) models of the coagulation cascade has improved, simulating the interactions between proteases, cofactors, regulators, fibrin, and therapeutic responses under different clinical scenarios. We aim to review the literature on QSP models to assess the unique capabilities and reusability of these models. We systematically searched the literature and BioModels database reviewing systems biology (SB) and QSP models. The purpose and scope of most of these models are redundant with only two SB models serving as the basis for QSP models. Primarily three QSP models have a comprehensive scope and are systematically linked between SB and more recent QSP models. The biological scope of recent QSP models has expanded to enable simulations of previously unexplainable clotting events and the drug effects for treating bleeding or thrombosis. Overall, the field of coagulation appears to suffer from unclear connections between models and irreproducible code as previously reported. The reusability of future QSP models can improve by adopting model equations from validated QSP models, clearly documenting the purpose and modifications, and sharing reproducible code. The capabilities of future QSP models can improve from more rigorous validation by capturing a broader range of responses to therapies from individual patient measurements and integrating blood flow and platelet dynamics to closely represent in vivo bleeding or thrombosis risk.
引用
收藏
页数:16
相关论文
共 24 条
  • [21] Stably Accelerating Stiff Quantitative Systems Pharmacology Models: Continuous-Time Echo State Networks as Implicit Machine Learning
    Anantharaman, Ranjan
    Abdelrehim, Anas
    Jain, Anand
    Pal, Avik
    Sharp, Danny
    Edelman, Alan
    Rackauckas, Chris
    Rackauckas, Chris
    IFAC PAPERSONLINE, 2023, 55 (23): : 1 - 6
  • [22] Understanding the Mechanisms and Treatment of Heart Failure: Quantitative Systems Pharmacology Models with a Focus on SGLT2 Inhibitors and Sex-Specific Differences
    Ndiaye, Jean Francois
    Nekka, Fahima
    Craig, Morgan
    PHARMACEUTICS, 2023, 15 (03)
  • [23] FDA-Industry Scientific Exchange on assessing quantitative systems pharmacology models in clinical drug development: a meeting report, summary of challenges/gaps, and future perspective
    Bai, Jane P. F.
    Schmidt, Brian J.
    Gadkar, Kapil G.
    Damian, Valeriu
    Earp, Justin C.
    Friedrich, Christina
    van der Graaf, Piet H.
    Madabushi, Rajanikanth
    Musante, Cynthia J.
    Naik, Kunal
    Rogge, Mark
    Zhu, Hao
    AAPS JOURNAL, 2021, 23 (03)
  • [24] FDA-Industry Scientific Exchange on assessing quantitative systems pharmacology models in clinical drug development: a meeting report, summary of challenges/gaps, and future perspective
    Jane P. F. Bai
    Brian J. Schmidt
    Kapil G. Gadkar
    Valeriu Damian
    Justin C. Earp
    Christina Friedrich
    Piet H. van der Graaf
    Rajanikanth Madabushi
    Cynthia J. Musante
    Kunal Naik
    Mark Rogge
    Hao Zhu
    The AAPS Journal, 23